2022
IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial
Kohli N, Lerner M, Rashty J, Kirke D, Stewart T, Blitzer A. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial. American Journal Of Otolaryngology 2022, 43: 103613. PMID: 36055061, DOI: 10.1016/j.amjoto.2022.103613.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOpen-label clinical trialProspective open-label trialAdductor laryngeal dystoniaOpen-label trialFirst-line treatmentVoice Handicap Index-10Side effect profileTransient side effectsNormal functionVHI-10 scoresIncobotulinumtoxinA injectionsEffect profileLine treatmentSystemic diseaseTA muscleBotulinum toxinClinical trialsLaryngeal dystoniaNursing womenThyroarytenoid muscleInjection sessionsExclusion criteriaSide effects
2020
Botulinum Toxin for the Treatment of Motor and Phonic Tics: A Case Report
Kohli N, Blitzer A. Botulinum Toxin for the Treatment of Motor and Phonic Tics: A Case Report. Annals Of Otology Rhinology & Laryngology 2020, 129: 625-627. PMID: 31906695, DOI: 10.1177/0003489419898211.Peer-Reviewed Original ResearchConceptsYale Global Tic Severity ScaleTreatment of motorPhonic ticsCase reportTic Severity ScaleFacial mimetic musculatureOnabotulinum toxinFiberoptic visualizationBotulinum toxinThroat clearingTic disordersSeverity ScaleTic severityObjective decreaseMimetic musculaturePatientsTreatmentLevel VExperienced reductionsMusculatureToxinReportGruntingBoNTSeverity